Vabysmo

E822409

Vabysmo is the brand name for faricimab, an injectable eye medication used to treat retinal diseases such as neovascular (wet) age-related macular degeneration and diabetic macular edema.

All labels observed (1)

Label Occurrences
Vabysmo canonical 1

How this entity was disambiguated

Statements (51)

Predicate Object
instanceOf angiogenesis inhibitor
bispecific monoclonal antibody
brand name drug
ophthalmic drug
pharmaceutical drug
adverseEffect conjunctival hemorrhage
eye pain
increased intraocular pressure
vitreous floaters
approvalYear 2022
approvedBy U.S. Food and Drug Administration
approvedIn European Union
United States
belongsToClass anti-VEGF agents
anti-angiopoietin agents
clinicalTrial LUCERNE
RHINE
TENAYA
YOSEMITE
comparedWith aflibercept
contraindication active intraocular inflammation
ocular or periocular infection
developedBy Genentech
Roche
hasATCCode S01LA07
hasDosageForm solution for intravitreal injection
hasDosingInterval every 4 weeks (loading phase)
up to every 16 weeks (maintenance phase, label-dependent)
hasGenericName faricimab
hasINN faricimab
hasMechanismOfAction inhibits VEGF-A and Ang-2 signaling pathways
reduces pathological ocular neovascularization
stabilizes retinal vasculature
indicationPopulation adults
legalStatus prescription only
marketedBy Genentech
Roche
routeOfAdministration intravitreal injection
seriousAdverseEffect endophthalmitis
retinal detachment
targets VEGF-A
angiopoietin-2
vascular endothelial growth factor A
therapeuticArea ophthalmology
treatsSymptom vision impairment due to diabetic macular edema
vision loss due to wet age-related macular degeneration
usedFor diabetic macular edema
macular edema following retinal vein occlusion
neovascular age-related macular degeneration
retinal vein occlusion
wet age-related macular degeneration

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

faricimab hasTradeName Vabysmo